PROBIOMED S.A. de C.V. Company Profile

Background

Overview

PROBIOMED S.A. de C.V. is a Mexican biopharmaceutical company established in 1970, specializing in the research, development, manufacturing, and commercialization of pharmaceutical and biotechnological products for human health. The company is renowned for its commitment to delivering high-technology solutions aimed at enhancing patient health and quality of life. Its extensive portfolio includes a wide range of generic chemical synthesis and biocomparable products, addressing various medical specialties such as family medicine, internal medicine, nephrology, neurology, oncology, dermatocosmetics, and beauty.

Mission and Vision

Mission: To provide the world with high-technology medicines that improve human health and the quality of life of patients.

Vision: To be the leading biopharmaceutical company in biocomparable medicines, from Mexico to the world.

Industry Significance

PROBIOMED holds a significant position in the Mexican pharmaceutical industry, being the only national company that develops biocomparable products entirely within the country. This integration of production chains has enabled PROBIOMED to offer high-quality products at affordable prices, thereby increasing patient access to necessary treatments.

Key Strategic Focus

Core Objectives

PROBIOMED aims to lead in the development and manufacturing of biocomparable medicines, ensuring that patients have access to effective and affordable treatments.

Areas of Specialization

Biocomparable Products: Development of biocomparable medicines, including cytokines, monoclonal antibodies, fusion proteins, and recombinant vaccines.

Medical Specialties: Focus on areas such as cardiology, surgery, dermatology, endocrinology, hematology, oncology, orthopedics, nephrology, neurology, traumatology, and urology.

Key Technologies Utilized

Recombinant DNA Technology: Employed in the production of biocomparable products, ensuring efficacy and safety.

Integrated Manufacturing: From gene to medicine, encompassing the entire production process within Mexico.

Primary Markets Targeted

PROBIOMED's products are marketed in various countries, including Guatemala, El Salvador, Honduras, Panama, the Dominican Republic, Peru, Bolivia, Paraguay, Uruguay, Thailand, and others.

Financials and Funding

Funding History

Specific details regarding PROBIOMED's funding history are not publicly disclosed.

Recent Developments

In May 2022, Sanfer Farma, one of the largest pharmaceutical groups in Mexico and Latin America, acquired a majority stake in PROBIOMED. This acquisition marks a significant development in the company's growth and expansion within the pharmaceutical sector.

Pipeline Development

Key Pipeline Candidates

PROBIOMED's pipeline includes a diverse range of biocomparable products targeting chronic-degenerative diseases, hematological and metabolic disorders, and malignant neoplasms. The company has developed over 70 products, with more than 12 biocomparables, addressing various medical specialties.

Stages of Development

The company has successfully developed and commercialized several biocomparable products, with ongoing research and development efforts to expand its portfolio.

Target Conditions

Chronic-Degenerative Diseases: Including conditions such as diabetes and cardiovascular diseases.

Hematological and Metabolic Disorders: Addressing diseases like anemia and metabolic syndrome.

Malignant Neoplasms: Focusing on various types of cancers.

Anticipated Milestones

While specific timelines for upcoming milestones are not publicly available, PROBIOMED continues to invest in research and development to introduce new biocomparable products to the market.

Technological Platform and Innovation

Proprietary Technologies

Integrated Biocomparable Development: From gene to medicine, ensuring control over the entire production process.

Significant Scientific Methods

Recombinant DNA Technology: Utilized in the production of biocomparable products.

Advanced Manufacturing Processes: Ensuring high-quality standards in product development.

AI-Driven Capabilities

Specific information regarding AI-driven capabilities within PROBIOMED is not publicly disclosed.

Leadership Team

Key Executives

Jaime Uribe de la Mora: Founder and CEO of PROBIOMED, leading the company's strategic direction and growth.

Leadership Changes

In May 2022, Sanfer Farma acquired a majority stake in PROBIOMED, potentially leading to changes in the leadership structure. However, specific details regarding leadership changes post-acquisition are not publicly available.

Competitor Profile

Market Insights and Dynamics

The Mexican pharmaceutical market is the second-largest in Latin America, valued at approximately $9.3 billion in annual sales. The industry is characterized by a mix of domestic and international players, with a growing emphasis on biotechnological advancements and the development of biocomparable products.

Competitor Analysis

Grupo Pisa: A leading pharmaceutical company in Mexico, focusing on a wide range of therapeutic areas.

Grupo Fármacos Especializados: Specializes in the development and commercialization of pharmaceutical products.

Grupo CPI: Engages in the production and distribution of pharmaceutical products.

Strategic Collaborations and Partnerships

In July 2011, PROBIOMED entered into an exclusive license agreement with Vanda Pharmaceuticals Inc. for the commercialization of Fanapt™ in Mexico, highlighting its commitment to expanding its product offerings and market reach.

Operational Insights

PROBIOMED's integrated approach to developing biocomparable products from gene to medicine provides a competitive advantage in ensuring product quality and affordability. The company's focus on research and development, coupled with its strategic partnerships, positions it favorably in the biopharmaceutical market.

Strategic Opportunities and Future Directions

Strategic Roadmap

PROBIOMED aims to expand its portfolio of biocomparable products, focusing on chronic-degenerative diseases, hematological and metabolic disorders, and malignant neoplasms. The company continues to invest in research and development to introduce innovative solutions to the market.

Future Business Directions

International Expansion: Leveraging the acquisition by Sanfer Farma to enhance distribution channels and market presence.

Product Diversification: Developing new biocomparable products to address unmet medical needs.

Technological Advancements: Integrating advanced technologies to improve manufacturing processes and product efficacy.

Opportunities for Expansion

The growing demand for affordable and effective biocomparable medicines presents significant opportunities for PROBIOMED to expand its market share both domestically and internationally.